Procaps Group S A Quick Ratio (PROCF) starting from the fourth quarter 2024 to fourth quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Procaps Group S a   (PROCF)

Procaps Group S A 's Quick Ratio

PROCF's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Procaps Group S A 's Cash & cash equivalent grew by 73.1 % in the Q4 2024 sequentially, while Current Liabilities decreased, this led to improvement in Procaps Group S A 's Quick Ratio to 0.2, above Procaps Group S a average Quick Ratio.

Within Major Pharmaceutical Preparations industry 534 other companies have achieved higher Quick Ratio than Procaps Group S A in fourth quarter 2024. While Quick Ratio total ranking has improved so far during the Q4 2024 to 4085, from total ranking in the fourth quarter 2023 at 4312.

Explain Quick Ratio?
How much Cash & cash equivalents PROCF´s has?
What are PROCF´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PROCF Quick Ratio (Dec 31 2024)
Q4		 (Dec 31 2023)
Q3		 0
Q2		 0
Q1		 0
Q4
Y / Y Current Liabilities Change -61.3 % 7.43 % 9.03 % 73.8 % 9.03 %
Y / Y Cash & cash equivalent Change 73.1 % -59.27 % -59.27 % -69.27 % -59.27 %
Quick Ratio MRQ 0.2 0.04 0.04 0.02 0.04
PROCF's Total Ranking # 4085 # 4312 # # #
Seq. Current Liabilities Change -68.58 % 23.17 % -37.26 % 59.4 % -12.78 %
Seq. Cash & cash equivalent Change 73.1 % 0 % 51.79 % -34.12 % -59.27 %



Quick Ratio fourth quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 535
Healthcare Sector # 1030
Overall Market # 4085


Quick Ratio Statistics
High Average Low
0.56 0.11 0
(Dec 31 2021)   (Dec 31 2019)




Financial Statements
Procaps Group S A 's Current Liabilities $ 155 Millions Visit PROCF's Balance sheet
Procaps Group S A 's Cash & cash equivalent $ 30 Millions Visit PROCF's Balance sheet
Source of PROCF's Sales Visit PROCF's Sales by Geography


Cumulative Procaps Group S A 's Quick Ratio

PROCF's Quick Ratio for the trailling 12 Months

PROCF Quick Ratio

 (Dec 31 2024)
12 Months		 (Dec 31 2023)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months
Y / Y Current Liabilities TTM Growth 5.82 % 23.8 % 54.26 % 42.69 % 16.07 %
Y / Y Cash & cash equivalent TTM Growth -45.5 % -61.53 % -54.22 % -26.67 % 16.22 %
Quick Ratio TTM 0.05 0.03 0.05 0.06 0.09
Total Ranking TTM # 4676 # 4098 # # #
Seq. Current Liabilities TTM Growth -12.7 % 1.8 % 1.78 % 17 % 2.13 %
Seq. Cash & cash equivalent TTM Growth 19.98 % -28.46 % -22.15 % -18.44 % -15.3 %

Quick ratio ranking by company, industry and sector >> Back to PROCF Financial Strength Comparisons >> Go to Compare PROCF Quick Ratio to its Competitors

On the trailing twelve months basis PROCF Cash & cash equivalent soared by 73.1 % in Q4 2024 year on year, while Current Liabilities dropped to $155 millions, this led to increase in in Procaps Group S A 's Quick Ratio to 0.05, Quick Ratio remained below PROCF average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 571 other companies have achieved higher Quick Ratio than Procaps Group S A . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2023 from 4098 to 4676.

Explain Quick Ratio?
How much Cash & cash equivalents PROCF´s has?
What are PROCF´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 572
Healthcare Sector # 1154
Within the Market # 4676


trailing twelve months Quick Ratio Statistics
High Average Low
0.11 0.07 0.04
(Dec 31 2022)   (Dec 31 2023)




Companies with similar Quick Ratio in the quarter ending Dec 31 2024, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2024 MRQ Cash & cash equivalentDec 31 2024 MRQ Current Liabilities
Supernus Pharmaceuticals inc   0.54 $ 69.331  Millions$ 129.532  Millions
Aurinia Pharmaceuticals Inc   0.53 $ 83.396  Millions$ 158.050  Millions
Optinose Inc   0.52 $ 84.485  Millions$ 162.813  Millions
23andme Holding Co  0.52 $ 79.350  Millions$ 153.340  Millions
Harrow Inc   0.52 $ 47.247  Millions$ 91.343  Millions
Tiziana Life Sciences Ltd  0.52 $ 3.724  Millions$ 7.230  Millions
Oragenics Inc   0.51 $ 0.865  Millions$ 1.684  Millions
Summit Therapeutics Inc   0.51 $ 16.363  Millions$ 31.874  Millions
Igc Pharma Inc   0.51 $ 1.198  Millions$ 2.343  Millions
Xencor Inc  0.50 $ 43.192  Millions$ 86.123  Millions
Bio Green Med Solution Inc   0.50 $ 3.137  Millions$ 6.268  Millions
Earth Science Tech Inc   0.50 $ 0.707  Millions$ 1.416  Millions
Biofrontera Inc   0.49 $ 5.905  Millions$ 12.021  Millions
Merck and Co Inc   0.48 $ 13,689.000  Millions$ 28,420.000  Millions
Immunoprecise Antibodies Ltd   0.48 $ 2.967  Millions$ 6.223  Millions
Elanco Animal Health Incorporated  0.48 $ 468.000  Millions$ 983.000  Millions
Bristol myers Squibb Company  0.46 $ 10,859.000  Millions$ 23,774.000  Millions
Citius Pharmaceuticals Inc   0.45 $ 3.252  Millions$ 7.156  Millions
Grifols Sa  0.45 $ 1,097.354  Millions$ 2,414.884  Millions
Biodexa Pharmaceuticals Plc  0.45 $ 2.242  Millions$ 5.034  Millions
Galectin Therapeutics Inc   0.43 $ 15.120  Millions$ 35.409  Millions
Jaguar Health Inc   0.41 $ 8.002  Millions$ 19.704  Millions
Prestige Consumer Healthcare Inc   0.40 $ 46.469  Millions$ 117.048  Millions
Ac Immune Sa  0.40 $ 40.003  Millions$ 100.838  Millions
Pharming Group N v   0.39 $ 54.944  Millions$ 140.413  Millions
Kyntra Bio Inc   0.38 $ 50.482  Millions$ 133.306  Millions
Psyence Biomedical ltd   0.38 $ 0.105  Millions$ 0.280  Millions
Lftd Partners Inc   0.36 $ 2.207  Millions$ 6.084  Millions
Novartis Ag  0.36 $ 11,592.000  Millions$ 32,048.000  Millions
Incannex Healthcare Inc  0.36 $ 2.098  Millions$ 5.840  Millions

Date modified: 2026-09-02T18:50:17+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.